InDex Pharma receives Korean patent for for cobitolimod to inflammatory bowel disease
InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company focusing on immunological diseases, announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Korean Intellectual Property Office. The patent provides protection for the use of cobitolimod in the treatment of inflammatory bowel disease.
The patent (patent number: 10-2592716) will provide an exclusivity period until August 2040, with the possibility of up to 5 years patent term extension upon market approval.
Corresponding patent applications have previously been granted in Europe and Hong Kong and filed in additional strategically important patent territories globally.
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is being evaluated in the phase III programme CONCLUDE as a novel treatment of moderate to severe left-sided ulcerative colitis – a debilitating, chronic inflammation of the large intestine.

Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!